J Infect Dis. 1995 May;171(5):1172-9.

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR.

Source

Beth Israel Hospital, Boston, Massachusetts, USA.

Abstract

Zidovudine resistance mutations at reverse transcriptase codons 215 or 41 were found in two-thirds of human immunodeficiency virus type 1 (HIV-1) isolates obtained at baseline from patients enrolled in an AIDS Clinical Trials Group (ACTG) protocol that compared didanosine with continued zidovudine in patients with > or = 16 weeks of previous zidovudine therapy (ACTG 116B/117). The combined presence of mutations at both codons 215 and 41 conferred an increased risk for progression (relative hazard, 1.82; 95% confidence interval [CI], 1.02-3.26) and an increased risk for death (RH, 5.42; 95% CI, 1.92-15.30) in analyses that controlled for other factors predictive of progression. However, the benefit of switching to didanosine compared with continued zidovudine therapy was independent of the presence of these mutations. Although this information is not helpful in determining when to alter therapy, detection of zidovudine resistance mutations provides prognostic information in patients with advanced HIV disease.

PMID:: 7538548; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Molecular Biology Databases

ZIDOVUDINE - HSDB

Supplemental Content

Save items

Related citations in PubMed

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. [Ann Intern Med. 1995]
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, et al. Ann Intern Med. 1995 Mar 15; 122(6):401-8.
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. [J Infect Dis. 1995]
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. J Infect Dis. 1995 Jul; 172(1):70-8.
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. [Ann Intern Med. 1994]
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Ann Intern Med. 1994 Aug 15; 121(4):263-8.
Review Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. [J Infect Dis. 1995]
Review Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
Johnson VA. J Infect Dis. 1995 Mar; 171 Suppl 2:S140-9.
Review Resistance, drug failure, and disease progression. [AIDS Res Hum Retroviruses. 1994]
Review Resistance, drug failure, and disease progression.
Richman DD. AIDS Res Hum Retroviruses. 1994 Aug; 10(8):901-5.

See reviews... See all...

Cited by 21 PubMed Central articles

A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. [HIV Seq Compend. 2001]
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.
Shafer RW, Dupnik K, Winters MA, Eshleman SH. HIV Seq Compend. 2001; 2001:1-51.
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions. [J Clin Microbiol. 2009]
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.
Hosoya N, Su Z, Wilkin T, Gulick RM, Flexner C, Hughes MD, Skolnik PR, Giguel F, Greaves WL, Coakley E, et al. J Clin Microbiol. 2009 Aug; 47(8):2604-6. Epub 2009 Jun 3.
Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility. [J Virol. 2009]
Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.
Puertas MC, Buzón MJ, Artese A, Alcaro S, Menendez-Arias L, Perno CF, Clotet B, Ceccherini-Silberstein F, Martinez-Picado J. J Virol. 2009 Aug; 83(15):7434-9. Epub 2009 May 20.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Prevalence and clinical significance of zidovudine resistance mutations in human...
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
J Infect Dis. 1995 May ;171(5):1172-9.

PubMed
The efficacy of postprostatectomy radiotherapy in patients with an isolated elev...
The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen.
Int J Radiat Oncol Biol Phys. 1995 May 15 ;32(2):317-23.

PubMed
Genetics of tuberose sclerosis.
Genetics of tuberose sclerosis.
Lancet. 1978 Feb 11 ;1(8059):340.

PubMed
Isolation, culture, and characterization of the two cell subpopulations forming ...
Isolation, culture, and characterization of the two cell subpopulations forming the rat decidua: differential gene expression for activin, follistatin, and decidual prolactin-related protein.
Endocrinology. 1995 Jun ;136(6):2451-8.

PubMed
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-...
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
J Clin Oncol. 1995 May ;13(5):1080-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 21 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information